GlassScriptPhysician profile
Mobin T Varghese
NPI 1114504248
$4,444.15
in general payments reported to CMS, 2019-2025
31 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $459 · 2023: $1,200 · 2024: $1,479 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,984.52 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $565.71 | 2023-2025 | Prevymis, Dificid |
| Veloxis Pharmaceuticals, INC. | $482.68 | 2022-2025 | Envarsus |
| Amgen INC. | $454.10 | 2023-2025 | Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $324.58 | 2022-2025 | Farxiga, Lokelma |
| Takeda Pharmaceuticals U.S.A., INC. | $294.89 | 2022-2025 | Livtencity |
| Novo Nordisk INC | $293.32 | 2023-2025 | Ozempic, Rybelsus, Rivfloza |
| Otsuka America Pharmaceutical, INC. | $290.23 | 2022-2025 | Jynarque |
| Horizon Therapeutics Plc | $254.77 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $209.54 | 2023-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $199.94 | 2022-2023 | Lupkynis |
| Cormedix INC. | $178.15 | 2024-2025 | Defencath, Defencath |
| Travere Therapeutics, INC. | $147.81 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $136.45 | 2023-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.70 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $66.80 | 2023 | Veltassa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $53.39 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $47.58 | 2024-2025 | |
| Kyowa Kirin, INC. | $47.42 | 2025 | |
| Glaxosmithkline, LLC. | $43.98 | 2024-2025 | Arexvy, Jesduvroq |
| Amarin Pharma, INC. | $36.40 | 2022 | |
| Ardelyx, INC. | $29.27 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $27.70 | 2022 | |
| Genentech USA, INC. | $23.43 | 2025 | Gazyva |
| Opko Pharmaceuticals, LLC | $21.49 | 2024 | Rayaldee |
| Genzyme Corporation | $21.44 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.02 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.68 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.45 | 2024 | |
| Scpharmaceuticals INC. | $16.04 | 2025 | |
| Dexcom, INC. | $15.85 | 2022 | |
| Fresenius USA Marketing, INC. | $13.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mobin Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.